Cigna Corp (NYSE:CI) Shares Sold by Truvestments Capital LLC
Truvestments Capital LLC reduced its position in Cigna Corp (NYSE:CI) by 26.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 170 shares of the health services provider’s stock after selling 61 shares during the quarter. Truvestments Capital LLC’s holdings in Cigna were worth $27,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new position in Cigna in the fourth quarter worth $737,238,000. FMR LLC raised its position in Cigna by 21.6% in the first quarter. FMR LLC now owns 12,229,261 shares of the health services provider’s stock worth $1,966,710,000 after acquiring an additional 2,171,463 shares in the last quarter. Geode Capital Management LLC raised its position in Cigna by 61.3% in the fourth quarter. Geode Capital Management LLC now owns 4,939,173 shares of the health services provider’s stock worth $936,405,000 after acquiring an additional 1,876,556 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Cigna by 82.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,539,322 shares of the health services provider’s stock worth $672,215,000 after acquiring an additional 1,600,531 shares in the last quarter. Finally, Boston Partners raised its position in Cigna by 34.7% in the first quarter. Boston Partners now owns 4,895,908 shares of the health services provider’s stock worth $787,360,000 after acquiring an additional 1,261,911 shares in the last quarter. 87.94% of the stock is owned by institutional investors and hedge funds.
Shares of CI stock opened at $167.30 on Friday. Cigna Corp has a fifty-two week low of $141.95 and a fifty-two week high of $226.60. The stock has a market capitalization of $63.20 billion, a PE ratio of 11.77, a P/E/G ratio of 0.86 and a beta of 0.71. The firm has a fifty day moving average price of $164.54. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.89.
Several research firms have issued reports on CI. UBS Group set a $36.00 price objective on Halliburton and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Barclays set a $24.00 price objective on Tenet Healthcare and gave the stock a “hold” rating in a research report on Wednesday, April 17th. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $23.00 to $24.00 in a research report on Monday, June 3rd. Goldman Sachs Group upgraded Puxin from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $51.00 to $56.00 in a research report on Friday, May 3rd. Finally, Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research report on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $217.40.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Read More: What is a blue-chip stock?
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.